DaVita Inc. (DVA): Price and Financial Metrics

DaVita Inc. (DVA)

Today's Latest Price: $88.28 USD

5.89 (7.15%)

Updated Jun 5 4:10pm

Add DVA to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 66 in Medical - Services

See all "A" rated Strong Buy stocks

DVA Stock Summary

  • The capital turnover (annual revenue relative to shareholder's equity) for DVA is 5.9 -- better than 92.87% of US stocks.
  • Over the past twelve months, DVA has reported earnings growth of 83.74%, putting it ahead of 87.46% of US stocks in our set.
  • Davita Inc's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is 46.49%, greater than the shareholder yield of 93.72% of stocks in our set.
  • Stocks that are quantitatively similar to DVA, based on their financial statements, market capitalization, and price volatility, are WYNN, LAMR, CE, OUT, and SYNH.
  • DVA's SEC filings can be seen here. And to visit Davita Inc's official web site, go to www.davita.com.
DVA Daily Price Range
DVA 52-Week Price Range

DVA Stock Price Chart More Charts

DVA Price/Volume Stats

Current price $88.28 52-week high $90.15
Prev. close $82.39 52-week low $46.36
Day low $82.80 Volume 2,848,998
Day high $88.70 Avg. volume 1,454,169
50-day MA $77.35 Dividend yield N/A
200-day MA $71.60 Market Cap 10.75B

DaVita Inc. (DVA) Company Bio

DaVita Healthcare Partners delivers dialysis services to patients with chronic kidney failure and end stage renal disease. The company was founded in 1994 and is based in Denver, Colorado.

DVA Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target:Forecasted Gain:

We started the process of determining a valid price forecast for Davita Inc with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that Davita Inc ranked in the 69th percentile in terms of potential gain offered. Specifically, our DCF analysis implies the stock is trading below its fair value by an estimated 154%. In terms of the factors that were most noteworthy in this DCF analysis for DVA, they are:

  • The stock's equity weight, or the proportion of capital from equity relative to debt, is 46. Notably, its equity weight is greater than just 11.87% of US equities in the Healthcare sector yielding a positive free cash flow.
  • Davita Inc's weighted average cost of capital (WACC) is 6%; for context, that number is higher than merely 3.4% of tickers in our DCF set.

Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price

For other companies in the Healthcare that have a similar discounted cashflow valuation profile (and ensuing price forecasts) as DVA, try NVO, QDEL, JAZZ, ABBV, and FTLF.

DVA Latest News Stream

Event/TimeNews Detail
Loading, please wait...

DVA Latest Social Stream

Loading social stream, please wait...

View Full DVA Social Stream

Latest DVA News From Around the Web

Below are the latest news stories about Davita Inc that investors may wish to consider to help them evaluate DVA as an investment opportunity.

DaVita Sets Up Classic Pattern

Keep your eyes open for new setups as the pullback could be temporary. DaVita setting up a cup with handle with 85.42 buy point. RS line lagging but if money rotates here it could be actionable.

Yahoo | June 4, 2020

Edited Transcript of DVA earnings conference call or presentation 5-May-20 9:00pm GMT

Q1 2020 DaVita Inc Earnings Call

Yahoo | June 3, 2020

Hedge Funds Have Never Been This Bullish On DaVita Inc (DVA)

We at Insider Monkey have gone over 821 13F filings that hedge funds and prominent investors are required to file by the SEC The 13F filings show the funds' and investors' portfolio positions as of March 31st, near the height of the coronavirus market crash. In this article, we look at what those funds think […]

Yahoo | May 29, 2020

Does DaVita’s (DVA) Stock Buyback Strategy Make Sense in This Market?

First Eagle Investment Management recently released its Q1 2020 Investor Letter, a copy of which you can download below. The First Eagle Fund of America posted a return of -23.72% for the quarter (without sales charge), underperforming its benchmark, the S&P 500 Index which returned -19.60% in the same quarter. You should check out First […]

Yahoo | May 29, 2020

Nephrology Practice Solutions Names New Chief Medical Officer

Nephrology Practice Solutions (NPS) today announced that Dr. Thao Truong Pascual has assumed the role of chief medical officer (CMO). As a subsidiary of DaVita, NPS owns or manages nephrology practices throughout the U.S. that manage care for patients with chronic kidney disease.

Yahoo | May 28, 2020

Read More 'DVA' Stories Here

DVA Price Returns

1-mo 10.13%
3-mo 7.87%
6-mo 22.42%
1-year 85.11%
3-year 37.83%
5-year 7.83%
YTD 17.66%
2019 45.80%
2018 -28.78%
2017 12.54%
2016 -7.90%
2015 -7.96%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.9319 seconds.